Li Qiaofang,Zhu Shuchai,Deng Wenzhao,et al.Clinical outcomes in different target volume for cervical and upper-thoracic esophageal cancer in definitive chemoradiotherapy[J].Chinese Journal of Radiological Medicine and Protection,2019,39(4):268-273
Clinical outcomes in different target volume for cervical and upper-thoracic esophageal cancer in definitive chemoradiotherapy
Received:September 21, 2018  
DOI:10.3760/cma.j.issn.0254-5098.2019.04.005
KeyWords:Esophageal cancer  Elective nodal irradiation(ENI)  Involved-field irradiation(IFI)  Definitive chemoradiotherapy  Prognostic factors
FundProject:
Author NameAffiliationE-mail
Li Qiaofang Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
Zhu Shuchai Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China sczhu1965@163.com 
Deng Wenzhao Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
Zhang Xueyuan Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
Song Chunyang Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
Wang Xuan Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
Yan Ke Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China  
Hits: 3487
Download times: 1747
Abstract::
      Objective To investigate the prognostic effects and failure patterns of different clinical target volumes of IMRT in definitive chemoradiotherapy for cervical and upper-thoracic esophageal cancer, in order to provide a reference for radiotherapy target area delineation. Methods A retrospective analysis was performed on the clinical data of 132 patients with cervical and upper-thoracic esophageal cancer who received definitive IMRT and concurrent chemotherapy in our hospital from 2010 to 2014. Seventy-one patients received elective nodal irradiation (ENI) and the other 61 patients received involved-field irradiation (IFI). The Kaplan-Meier method was used to calculate local control (LC), progression-free survival (PFS) and overall survival (OS) rates. The significant difference was evaluated by the log-rank test. The prognostic factors were determined by Cox univariate and multivariate analyses. Results The last follow-up time was December 2017, the median follow-up time was 59.5 (14.2-95.8) months. Follow-up rate was 99.2%. For the ENI and IFI groups, the 1-, 3-, 5-year LC were 77.5%, 58.8%, 48.8% vs. 64.3%, 29.1%, 26.2% (χ2=9.68, P=0.002), PFS were 68.6%, 37.7%, 25.9% vs. 47.5%, 17.2%, 3.6% (χ2=11.39, P=0.001), OS were 81.7%, 53.9%, 31.3% vs. 70.5%, 31.9%, 16.3% (χ2=7.70, P=0.006), respectively. In multivariate analysis, T stage, N stage, and RT field were independent factors for LC, PFS and OS(P<0.05). The total failure rates, local-regional recurrent rate in ENI group were lower than those in IFI group (χ2=13.23, 5.24, P<0.05). No significant differences were found in acute radiation esophagitis, pneumonitis and myelosuppression (Grades ≥ 3) between the two groups(P>0.05). Conclusions Compared with IFI, ENI can significantly reduce local-regional recurrence and distant metastasis and improve the long-term survival for cervical and upper-thoracic esophageal cancer patients who received definitive chemoradiotherapy.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:12028854  On-line:0

v
Scan QR Code
&et=3C06DB566315F8DC438148F1AEA1AA224A2B0065396D874861568E476F8EA678712CD490A466FB9CBC693487AFAFC082BB1D3CDE356FA7E54477D7CD9253776B1538800BBDB42E22A0030C12418344ABE9987431DCB69AA2CAC04543ECA424EAD3E150A4A3411365781A12E17BEA27A312C8DBAB674809B6D316AFB489A98B86&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=B6351343F4791CA3&aid=C287CD5914DB95B0A67EE6D12E8AB279&vid=&iid=E158A972A605785F&sid=DC330B09A33F1455&eid=9F8C5EF901EA1E7E&fileno=20190405&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="B6351343F4791CA3"; var my_aid="C287CD5914DB95B0A67EE6D12E8AB279";